daunorubicin has been researched along with s 1033 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bao, W; Chen, BA; Cheng, J; Ding, JH; Gao, C; Gao, F; Shan, XY; Song, HH; Sun, YY; Wang, F; Wang, J; Wang, XM; Xia, GH; Xu, WL; Zhao, G | 1 |
| Bao, W; Chen, BA; Cheng, J; Cui, TY; Ding, JH; Gao, C; Gao, F; Schmitt, A; Schmitt, M; Shan, XY; Xia, GH; Zhong, YJ | 1 |
| Bukvova, R; Dolezel, P; Kosztyu, P; Mlejnek, P | 1 |
| Ahn, JS; Chi, HS; Cho, YU; Chung, JS; Eom, HS; Hyun, MS; Jang, S; Joo, YD; Jung, CW; Kim, DH; Kim, DY; Kim, H; Kim, I; Kim, K; Kim, KH; Kim, SD; Kim, YS; Lee, GW; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Mun, YC; Park, CJ; Park, J; Park, JH; Park, S; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yoon, SS | 1 |
1 review(s) available for daunorubicin and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for daunorubicin and s 1033
| Article | Year |
|---|---|
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vincristine | 2015 |
3 other study(ies) available for daunorubicin and s 1033
| Article | Year |
|---|---|
[Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
[Inducing apoptosis and reversal effect of nilotinib in combination with tetrandrine on multidrug resistance of K562/A02 cell line].
Topics: Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Pyrimidines; Survivin | 2011 |
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Pyrimidines | 2014 |